Dianthus Therapeutics
DNTH
39 hedge funds and large institutions have $107M invested in Dianthus Therapeutics in 2023 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 10 increasing their positions, 7 reducing their positions, and 1 closing their positions.
900% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 1
79% more capital inflows, than outflows
Capital inflows: $4.85M | Capital outflows: $2.72M
43% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 7
30% more funds holding
Funds holding: 30 → 39 (+9)
1.43% more ownership
Funds ownership: 68.01% → 69.44% (+1.4%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OCA
Octagon Capital Advisors
New York
|
+$817K |
| 2 |
Fred Alger Management
New York
|
+$451K |
| 3 |
Millennium Management
New York
|
+$375K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$317K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$296K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$1.44M |
| 2 |
TCM
Tang Capital Management
San Diego,
California
|
-$965K |
| 3 |
Laurion Capital Management
New York
|
-$112K |
| 4 |
Nantahala Capital Management
New Canaan,
Connecticut
|
-$93.1K |
| 5 |
RBF Capital
San Francisco,
California
|
-$54K |
DNTH Hedge Fund Activity: Q4 2023 in Review
39 of the 6,875 institutional investors tracked by Wall St. Rank reported a position in Dianthus Therapeutics (DNTH) for Q4 2023, worth a combined $107M — down 22% from $136M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new DNTH positions and 1 closed out — a net gain of 9 holders — while 10 added to existing stakes and 7 trimmed.
The largest buyer was Octagon Capital Advisors, adding an estimated $817K. The largest seller was Citadel Advisors, exiting entirely with an estimated $1.44M sold.
- 39 institutional investors held Dianthus Therapeutics (DNTH) as of Q4 2023, up from 30 in Q3 2023.
- Funds reported $107M of Dianthus Therapeutics stock for Q4 2023, down 22% quarter-over-quarter.
- 10 funds opened new Dianthus Therapeutics positions in Q4 2023 and 1 closed out, a net change of +9 holders.
- The largest Dianthus Therapeutics buyer in Q4 2023 was Octagon Capital Advisors, an estimated $817K added.
- The largest Dianthus Therapeutics seller in Q4 2023 was Citadel Advisors, an estimated $1.44M sold.
Based on aggregated 13F filings for Q4 2023.